IE38521L - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- IE38521L IE38521L IE732082A IE208273A IE38521L IE 38521 L IE38521 L IE 38521L IE 732082 A IE732082 A IE 732082A IE 208273 A IE208273 A IE 208273A IE 38521 L IE38521 L IE 38521L
- Authority
- IE
- Ireland
- Prior art keywords
- acid
- aluminium
- glycyrrhetininc
- salts
- antacid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 abstract 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 abstract 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- 229940069428 antacid Drugs 0.000 abstract 2
- 239000003159 antacid agent Substances 0.000 abstract 2
- 230000001458 anti-acid effect Effects 0.000 abstract 2
- 229960003720 enoxolone Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001399 aluminium compounds Chemical class 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 229940001007 aluminium phosphate Drugs 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 abstract 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- -1 antacid aluminium compound Chemical class 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229910052797 bismuth Inorganic materials 0.000 abstract 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 235000012254 magnesium hydroxide Nutrition 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 abstract 1
- 235000019793 magnesium trisilicate Nutrition 0.000 abstract 1
- 229940099273 magnesium trisilicate Drugs 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 230000001562 ulcerogenic effect Effects 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1401360 Pharmaceutical compositions BIOREX LABORATORIES LTD 29 Nov 1973 [18 Dec 1972] 58355/72 Heading A5B Pharmaceutical compositions for use in the treatment of gastritis in dosage unit form comprise 1-100 mg of at least one non-ulcerogenic, anti-inflammatory active derivative of glycyrrhetinic acid (selected from the esters, hemiesters and hemiester salts thereof e.g. the disodium salt of glycyrrhetininc acid hemisuccinate, the salts of glycyrrhetinic acid with non-toxic organic bases; the salts of glycyrrhetinic acid and its hemiesters with bismuth, zinc or a metal of Group IIA, IIIA or VIII of the Periodic Table; and the amides of glycyrrhetininc acid and of acylated glycyrrhetininc acid), in admixture with 1-70% by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound (such as aluminium hydroxide, aluminium magnesium silicate, aluminium phosphate, or dihydroxyaluminium aminoacetate). The antacid aluminium compound may be partially replaced by other known antacid compounds e.g. calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate or sodium bicarbonate. The composition may be administered orally in the form of a tablet.
[GB1401360A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5835572A GB1401360A (en) | 1972-12-18 | 1972-12-18 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE38521L true IE38521L (en) | 1974-06-18 |
| IE38521B1 IE38521B1 (en) | 1978-03-29 |
Family
ID=10481403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2082/73A IE38521B1 (en) | 1972-12-18 | 1973-11-16 | Pharmaceutical composition |
Country Status (10)
| Country | Link |
|---|---|
| AU (1) | AU476390B2 (en) |
| BE (1) | BE802701A (en) |
| CA (1) | CA1018457A (en) |
| DE (1) | DE2360889A1 (en) |
| FR (1) | FR2210400B1 (en) |
| GB (1) | GB1401360A (en) |
| IE (1) | IE38521B1 (en) |
| IL (1) | IL42314A (en) |
| NL (1) | NL7317237A (en) |
| ZA (1) | ZA732439B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES511731A0 (en) * | 1981-06-01 | 1983-07-01 | Orion Yhtymae Oy | "A METHOD FOR PREPARING TABLETS BASED ON ACIDIC MEDICINE POWDERS, SAFE FOR THE ESOPHAGUS". |
| GB2122893B (en) * | 1982-06-30 | 1985-06-26 | Biorex Laboratories Ltd | Glycyrrhetinic acid compositions |
| AU553789B2 (en) * | 1982-06-30 | 1986-07-24 | Biorex Laboratories Ltd. | Glycyrrhetinic acid derivatives in cream compositions |
| US4861591A (en) * | 1987-11-18 | 1989-08-29 | American Home Products Corporation | Formulations for hygroscopic pharmaceuticals |
-
1972
- 1972-12-18 GB GB5835572A patent/GB1401360A/en not_active Expired
-
1973
- 1973-04-09 ZA ZA732439A patent/ZA732439B/en unknown
- 1973-05-20 IL IL42314A patent/IL42314A/en unknown
- 1973-07-23 BE BE133790A patent/BE802701A/en not_active IP Right Cessation
- 1973-07-30 FR FR7327833A patent/FR2210400B1/fr not_active Expired
- 1973-11-16 IE IE2082/73A patent/IE38521B1/en unknown
- 1973-11-30 AU AU63127/73A patent/AU476390B2/en not_active Expired
- 1973-12-06 DE DE2360889A patent/DE2360889A1/en not_active Withdrawn
- 1973-12-17 NL NL7317237A patent/NL7317237A/xx not_active Application Discontinuation
- 1973-12-17 CA CA188,350A patent/CA1018457A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2210400B1 (en) | 1977-07-15 |
| IL42314A0 (en) | 1973-07-30 |
| ZA732439B (en) | 1974-03-27 |
| DE2360889A1 (en) | 1974-06-20 |
| GB1401360A (en) | 1975-07-16 |
| BE802701A (en) | 1974-01-23 |
| CA1018457A (en) | 1977-10-04 |
| AU476390B2 (en) | 1976-09-16 |
| IL42314A (en) | 1976-09-30 |
| FR2210400A1 (en) | 1974-07-12 |
| IE38521B1 (en) | 1978-03-29 |
| AU6312773A (en) | 1975-06-05 |
| NL7317237A (en) | 1974-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE38520B1 (en) | Pharmaceutical composition | |
| ES8107207A1 (en) | Cephem and cepham compounds, processes for their preparation, pharmaceutical compositions containing them. | |
| ES480605A1 (en) | o-Substituted (+)-cyanidan-3-ol derivatives, method for their preparation, as well as pharmaceutical compositions containing these compounds and their preparation. | |
| IE38521L (en) | Pharmaceutical composition | |
| IE33477B1 (en) | Naphthacene derivatives | |
| WO1993020796A1 (en) | Method and composition for treating acne | |
| JPS5673089A (en) | Therapeutic creatinolloophosphate derivative* its manufacture* related pharmaceutic composition and therapy | |
| ES480147A1 (en) | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them. | |
| SU1251904A1 (en) | Composition for mineralization of teeth | |
| US3787581A (en) | Pharmaceutical compositions and methods of treatment | |
| US3501577A (en) | Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate | |
| GB1265627A (en) | ||
| ES8305759A1 (en) | Pyrrolidinone derivatives, their preparation and pharmaceutical compositions containing them. | |
| GB1243159A (en) | Sulphuric acid half-esters of tragacanth and preparation thereof | |
| US3968145A (en) | Methyl 2(1 chloronaphth-2-yloxy)propionate | |
| CH652923A5 (en) | PHARMACEUTICAL COMPOSITION FOR INFECTED RENAL CALCULOSIS THERAPY. | |
| IE44704L (en) | ß-LACTAM ANTIBIOTIC | |
| US4397862A (en) | Gastrointestinal sparing thioester drugs | |
| GB1276589A (en) | 0-alkyl-6-azauracil compounds and compositions containing the same | |
| Yendt | Drugs used in the management of renal calculi | |
| GB1217822A (en) | Pharmaceutical compositions | |
| GB1342540A (en) | Sulphonic acid esters their preparation and their medicinal use | |
| GB1220793A (en) | Pharmaceutical compositions | |
| Raiford | The use of banthine in ophthalmology | |
| GB1280244A (en) | Serum triglyceride-lowering compositions |